TEL is a new member of the ETS family of transcription factors which is rearranged in a number of hematologic malignancies with translocations involving chromosome band 12~13. In some cases, both TEL alleles are affected, resulting in loss of wild-type TEL function in the leukemic cells. In addition, 5% of children with acute lymphoblastic leukemia (ALL) have 12p12-pl3 deletions, suggesting that a tumor suppressor gene resides on 12p. These observations led us to consider whether TEL loss of function may contribute to the pathogenesis of ALL. In this report we show that the TEL gene maps between the polymorphic markers D12S89 and D12S98, and we use these flanking markers to screen HE GENETIC BASIS of acute lymphoblastic leukemia (ALL) is becoming better understood as the common chromosomal rearrangements associated with the disease are cloned. Among the best studied of these abnormalities are DNA rearrangements that result in overexpression of otherwise normal transcription factors as a consequence of their juxtaposition with either Ig or T-cell receptor regulatory elements. Examples include overexpression of MYC in B-cell leukemias,' and overexpression of SCL/TALl or RBTNl in T-cell Another class of transforming proteins implicated in the pathogenesis of ALL includes chimeric proteins resulting from chromosomal translocations. For example, the BCR-ABL fusion protein is the consequence of the t(9;22) (q34;qll) translocation, or Philadelphia chromosome, and 
TEL is a new member of the ETS family of transcription factors which is rearranged in a number of hematologic malignancies with translocations involving chromosome band 12~13. In some cases, both TEL alleles are affected, resulting in loss of wild-type TEL function in the leukemic cells. In addition, 5% of children with acute lymphoblastic leukemia (ALL) have 12p12-pl3 deletions, suggesting that a tumor suppressor gene resides on 12p. These observations led us to consider whether TEL loss of function may contribute to the pathogenesis of ALL. In this report we show that the TEL gene maps between the polymorphic markers D12S89 and D12S98, and we use these flanking markers to screen HE GENETIC BASIS of acute lymphoblastic leukemia (ALL) is becoming better understood as the common chromosomal rearrangements associated with the disease are cloned. Among the best studied of these abnormalities are DNA rearrangements that result in overexpression of otherwise normal transcription factors as a consequence of their juxtaposition with either Ig or T-cell receptor regulatory elements. Examples include overexpression of MYC in B-cell leukemias,' and overexpression of SCL/TALl or RBTNl in T-cell Another class of transforming proteins implicated in the pathogenesis of ALL includes chimeric proteins resulting from chromosomal translocations. For example, the BCR-ABL fusion protein is the consequence of the t(9;22) (q34;qll) translocation, or Philadelphia chromosome, and results in unregulated ABL tyrosine kinase activity.'" Chimeric transcription factors such as the E2A-PBX1 fusion arising from the t(1; 19)(q23;p13) translocation in pre-B ALL have been shown to act as dominant transforming proteins in cell culture and animal A number of fusion partners have also been identified for the MLL gene, which is frequently rearranged in leukemias with translocations involving 1 1q23.I4
A recent addition to this group of chimeric transcription factors is the TEL-AMLl fusion, which is the consequence of the t(12;21)(p13;q22) associated with childhood pre-B ALL.'' AMLl is the DNA-binding subunit of core binding factor (CBF), and has also been implicated in the pathogenesis of myeloid leukemias." TEL is a putative transcription factor belonging to the ETS family of DNA-binding proteins, and was initially identified because of its fusion to the platelet-derived growth factor receptor p gene in chronic myelomonocytic leukemia (CMML)." One of the striking findings in patients with TEL-AML1 fusions is that the other TEL allele is deleted, resulting in foss of wild-type TEL function in the leukemic cells. Loss of wild-type TEL function is similarly observed in some patients with TEL-ABL fusions, in which one TEL allele is disrupted by a chromosomal translocation, and the other allele is deleted.'* These findings led us to consider whether loss of TEL function may contribute to the pathogenesis of human leukemia. The TEL gene maps to chromosome band 12~13, a region of the genome that is involved in cytogenetically apparent deletions in 5% of childhood In addition, fluorescence in situ hybridization (FISH) analysis of hematologic malignancies selected for the presence of cytogenetically evident deletions of 12p13 showed that the TEL gene is within the commonly deleted region of 12p." However, the incidence of loss of heterozygosity (LOH) at this locus is not known. In this report we place the TEL gene on the emerging chromosome 12 physical map, identify neighboring polymorphic microsatellite markers, and use these markers to screen for LOH at the TEL gene locus in a large series of patients with childhood ALL. We find that TEL is deleted in 15% of children with ALL, representing one of the 
MATERIALS AND METHODS
Identification of yeast artifcial chromosomes (YACs) containing the TEL gene. A series of YACs mapping to 12p12-pl3 was screened by polymerase chain reaction (PCR) using oligonucleotide primers derived from the 3' untranslated region of the TEL cDNA. Primers 350-1 (5'-GGAATCTCTCCATCTGTAATTCCTCAC-CTGA-3') were used in 30 cycles of PCR (94°C X 1'; 58°C X l'; 72°C X 1 ') to amplify a 250-bp fragment from genomic DNA. YACs positive for TEL by PCR were confirmed by Southern blotting using a full-length TEL cDNA probe as previously described." The KIPlcontaining YAC 954g10 was similarly obtained using the primers CCT-3') and 350-2 (5"CCACGTGGCAGGAAAAAGAGGAAC-77 (5"TTGCCGAGTTCTACTACAGA-3') and 80 (5"TGCGTC-CACAAATGCGTGTC-3').
FISH. Bone marrow (BM) cells from a patient with CMML and t(5; 12)(q33;p13) translocation (patient 1 in reference 17) were cultured overnight and arrested in metaphase with colcemid. After fixation in methano1:acetic acid 3:1, the cells were air dried on glass slides. Total yeast DNA from a clone containing YAC 912d5 was biotinylated using a nick translation kit (BRL, Gaithersburg, MD) and purified over a Sephadex G-50 (Pharmacia, Piscataway, NJ) spin column. A cosmid mapping to 5p was similarly prepared, and was used to identify chromosome 5. The chromosome 12-specific centromeric probe was purchased from Oncor. Hybridization was performed as previously described," and the probes were detected with fluorescein avidin (Vector Laboratories, Burlingame, CA). The images were visualized on a Zeiss Axioskop epifluorescence microscope coupled to a cooled CCD camera. The fluorescein and propidium iodide images were recorded separately as gray-scale images, pseudocolored and merged using Gene Join and Adobe Photoshop.
Patient eligibility and sample preparation. Children less than 18 years of age who were enrolled on Dana-Farber Cancer Institute protocols 87-001 or 91-001 for childhood ALL between February 1, 1991 and May 31, 1993, were eligible for study. Patient samples were procured with informed consent. Only patients for whom BM samples were available at diagnosis and for whom either BM or peripheral blood (PB) samples were available during remission were studied. Selection of patients was made without regard to BM karyotype, immunophenotype, or clinical course. After mononuclear cell isolation by Ficoll sedimentation, 10 pL of the mononuclear cell pellet was boiled for 10 minutes in 100 pL water and centrifuged for 5 minutes at 12,OOOg. One microliter of the supernatant was used for PCR. In some cases, genomic DNA was prepared using standard methods," and 20 to 100 ng of DNA was used for PCR.
Microsatellite PCR analysis. Forty cycles of PCR (94°C X 1'; 58°C X l'; 72°C X 1') were performed using an MJ (Watertown, MA) thermal cycler as previously described." One of the oligonucleotide primers was end-labeled with y3'P-ATP using polynucleotide kinase (New England Biolabs, Beverly, MA). The primer combinations, some of which have been previously reported:' are shown in Table 1 . PCR products were separated on formamide-containing polyacrylamide gels, and were visualized by autoradiography. Genotypes were scored, and LOH was assigned when a microsatellite allele was absent at diagnosis but present in remission.
RESULTS
Genomic localization of the TEL gene. To facilitate the study of loss of heterozygosity at the TEL locus, it was necessary to determine its precise genomic localization. A series of YACs mapping to 12p12-pl3 was obtained from the CEPH mega-YAC library based on YAC sequence tagged site (STS) content (P.B.-W., D.C.W., unpublished results, March 1994), and these YACs were then screened by PCR. Oligonucleotide primers derived from the 3' untranslated region of TEL identified the following YACs: 912d5, 964~10, 74883, 720hl1, and 958b8. Southern blotting of PCR-positive YACs with a full-length TEL cDNA verified the presence of the TEL gene on these clones (data not shown).
To confirm the mapping of TEL to these YACs, TELpositive YACs were used as probes for metaphase FISH analysis of a patient with t(5; 12)(q33;p13) CMML, which is known to disrupt the TEL gene." As shown for YAC 912d5 in Fig 1, one YAC signal was visualized on the normal copy of chromosome 12, and the other YAC signal was split between the derivative chromosome 12 and the derivative chromosome 5. This result showed that YAC 912d5 indeed contained the TEL gene, enabling the TEL locus to be integrated into the existing 12p physical map.
Based on the STS content of TEL-positive YACs, the TEL gene was placed between the markers D12S89 and D12S98 (Fig 2) . D12S89, TEL, and D12S98 are all present on the 720-kb YAC 720hl1, suggesting that the maximum distance separating D12S89 and D12S98 is 720 kb. Figure 2 also illustrates the close proximity of the TEL gene to the KIPl gene encoding the cyclin-dependent kinase (cdk) inhibitor ~2 7 ?~. " k7Pl maps to the 1,520-kb YAC 954g10:' which overlaps with the 1,390 kb TEL YAC 964~10. The maximum distance separating TEL and KIP1 is therefore 2,910 kb, although the actual distance is likely smaller, because there is some overlap between the two YACs.
Screening for LOH ut the TEL locus. Having localized the TEL gene relative to known markers in the region (Fig   2) , the flanking polymorphic microsatellite markers D12S89 and D12S98 were used to screen matched pairs of leukemic and remission samples obtained from children with ALL who were treated on Dana-Farber Cancer Institute protocols 87-001 or 91-001. Eighty-one patients were eligible for study. Analysis of remission marrow or PB samples showed that 63/81 (78%) of patients were informative (heterozygous) at D12S89, and 53/81 (65%) were informative at D12S98. Leukemic BM samples of informative patients were then screened for LOH at D12S89 and D12S98 ( Table 2) . Nine of 63 (14%) patients had LOH at marker D12S89. The same 9 patients (9/53 or 17%) had LOH at D12S98. Because D12S89 and D12S98 flank the TEL gene, the incidence of LOH at the TEL locus in this childhood ALL population is also 14% to 17%, or approximately 15%.
The nine patients with TEL LOH were studied in more detail to determine the extent of the deletions in each patient. Ten additional polymorphic microsatellite markers were placed on the physical map (K.T.M., K.S.K., unpublished results, 1994) and were analyzed for LOH. An example of this type of analysis is shown for patient 4 in Fig 3. Patient   4 had LOH at markers D12S89, D12S98, and D123358, was not informative at D12S364, and showed no LOH at markers D12S336 and D12S363. The results using all markers in the nine patients with TEL LOH are shown schematically in Fig  4. A critically deleted region bordered by the telomeric marker D12S77 and the centromeric marker D12S70 was delineated. This region, deleted in all nine patients, contains both the TEL gene and the gene encoding p27, KIPI.
Using the Fisher exact test algorithm,29 there was no correlation between LOH at the TEL locus and patient gender, age at diagnosis, immunophenotype, risk group, or remission status, although the duration of follow-up is short (data not shown). Cytogenetic analysis was available for 58/81 (72%) patients evaluated. Only 1 of the 58 patients had cytogenetic findings suspicious for loss of genetic material from 12p, and this patient (patient 8) was among the nine patients who exhibited LOH at the TEL locus (Table 3) . Patient 8 has extra material on the short arm of chromosome 12
[add( 12p)], likely the result of an unbalanced translocation. Such an unbalanced translocation would result in the loss of the telomeric portion of 12p. The remainder of the patients with TEL LOH had deletions too small to be detectable by routine cytogenetic analysis.
DISCUSSION
Interstitial deletions of the short arm of chromosome 12 have been observed at the cytogenetic level in a wide variety of hematopoietic neoplasms, and are particularly common in childhood ALL.I9 This has led to the hypothesis that a tumor suppressor gene may map to 12pl2-pl3, although candidate genes have not been identified. In this report we have shown that LOH at the TEL gene locus on 12p I3 occurs in approximately 15% of childhood ALL, thus ranking it among the most common genetic abnormalities identified in childhood cancer. It is not surprising that the frequency of LOH detected by PCR is considerably higher than the 5% incidence of 12p deletions reported at the cytogenetic level, because small deletions may not be detectable by routine cytogenetic analysis. In fact, only one of the patients with TEL LOH in this study for whom BM karyotypes were available showed cytogenetic evidence of 12p deletion.
The screening strategy used in this study used two polymorphic microsatellite markers (D12S89 and D1 2898) which flank the TEL gene. This approach offers several advantages compared with other methods of screening for gene deletion, such as interphase FISH, competitive genomic hybridization, and Southern blotting. First, only small amounts of genomic DNA are needed for this PCR-based assay, facilitating the screening of large numbers of patients efficiently. Second, because the patients' normal heterozygous hematopoietic cells serve as the internal control, the need for quantitative Southern blotting techniques to measure gene dosage Eighty-one remission BM or PB samples were analyzed at the indicated microsatellite markers. Patients were judged to be informative if heterozygous at that locus. Leukemic marrow samples from informative patients were analyzed for loss of one of the two alleles, indicative of LOH. were amplified with 32P-labeled primers and the PCR products visualized by autoradiography after separation on polyacrylamide gels. There is no LOH at marker D12S336 or D12S363, because the ratio of the upper and lower alleles is the same in the L and R samples. For many markers, the lower allele is preferentially amplified compared with the upper allele. Markers D12S89, D12S98, and D12S358 show LOH, exhibiting a relative diminution of one of the two alleles in the leukemic sample. The deleted allele is not entirely absent because some normal cells are present in the marrow sample. The patient is homozygous at D12S364, and therefore not informative.
is not required. Finally, the integration of microsatellite markers into the expanding physical map facilitates the use of ordered, neighboring markers to delineate the precise boundaries of deletions in individual patients. One limitation of PCR-based screening methods is that only heterozygous individuals can be evaluated for LOH. For the marker D12S89, for example, only 78% of the 81 patients studied were informative. In addition, gene duplication, resulting in PCR amplification of one allele in excess of the other, can be mistaken for gene deletion. The determination of the precise incidence of TEL LOH in hematologic malignancy will require larger studies using multiple genetic markers and complementary techniques for assessing gene dosage.
The Critically deleted region of 12p. Microsatellite analysis of the 9 patients with LOH at the TEL locus is shown. Leukemic and remission marrow samples were amplified with the indicated microsatellite markers and assessed for LOH. The critical region deleted in all patients is bordered by D12S77 and D12S70, and includes both TEL and KIP1. +1,+5,+6,+6,+8,+10,+11,+12,-14,+15,+17, ,-13,+16,-21,de1~2)(q23q33),add~12p~,+mar,+mar 
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No evaluable metaphases were obtained from patient 1. patients whether loss of TEL function alone is oncogenic, or whether deletion of the other allele serves to potentiate the activity of dominant fusion proteins involving TEL.
TEL is a new member of the ETS family of transcription factors, joining FLI-1 and ERG as ETS proteins associated with human ~a n c e r .~' .~~ However, to date there is no direct evidence implicating ETS proteins as tumor suppressors. Interestingly, of all the ETS family members, TEL is most homologous to the Drosophila ETS protein yan, a transcriptional repressor.32s33 Whether TEL is also a transcriptional repressor has yet to be determined.
KIPl, the gene encoding p27, also maps within the critically deleted region of 12p identified in this study. p27 is an inhibitor of the cyclin D-cdk4 and cyclin E-cdk2 complexes and thereby participates in regulation of the GUS transition of the cell c y~l e . *~* *~ Therefore, p27 is an excellent candidate for a tumor suppressor, particularly because loss of function of other regulators of G1 progression, such as RB and has been identified in human t~~m o r s .~~-~* If either TEL or KIPl is indeed a tumor suppressor gene, then mutations affecting the structure or expression of the residual allele should be identifiable in tumors with LOH at this locus. Sequence analysis of TEL will be greatly facilitated by the elucidation of the TEL genomic structure, which is currently not known. To date, no mutations in the KIPl gene have been reported in human tumors, but extensive mutational analysis has not yet been p e r f~r r n e d .~~*~ It is also possible that an as-yet-unidentified tumor suppressor gene is located within the critically deleted region. Further refinement of the physical map in this region will be required to identify additional candidate genes. The finding of frequent LOH at the TEL locus in childhood ALL suggests that the identification of the 12p tumor suppressor gene may provide insight into the genetic basis of ALL, the most cornmon malignancy of ~hildhood.~'
